Department of Clinical Epidemiology and Evidence-based Medicine, the First Affiliated Hospital, China Medical University, Shenyang, China.
Department of Clinical Epidemiology and Evidence-based Medicine, and Department of Medical Record Management Center, the First Affiliated Hospital, China Medical University, Shenyang, China.
Clin Exp Rheumatol. 2021 Jul-Aug;39(4):829-837. doi: 10.55563/clinexprheumatol/y562nj. Epub 2020 Oct 17.
The purpose of this study was to determine the expression of related genes in patients with rheumatoid arthritis (RA) treated with methotrexate (MTX), to identify hub genes, and to systematically analyse the functions, pathways, and networks of these genes.
The PubMed identifiers (PMIDs) of relevant publications were obtained from the PubMed database, and gene data were extracted from these documents using the text mining software PubTator. The Database for Annotation, Visualization and Integrated Discovery (DAVID) was used to obtain enriched Gene Ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway information. In addition, the STRING database was used to construct a protein-protein interaction (PPI) network. Genes with which at least 10 other genes interacted were identified as hub genes.
A total of 216 genes were identified as being associated with treatment efficacy for MTX, of which 14 pathways exhibited significant correlation (p<0.05, FDR<0.05). In addition, the constructed MTX treatment-related network consisted of 267 interactions. Fourteen genes were found to interact with at least 10 other genes (p<0.05, FDR<0.05) and identified as hub genes in the PPI network. These genes were JAK1, MAPK1, JUN, AKT1, MAPK14, MAPK8, FGB, FN1, ALB, B2M, IL2RB, GGH, IL2RA, and TP53.
This study will assist in elucidating the molecular mechanisms associated with the treatment efficacy of MTX for RA and provide a scientific rationale for guiding patient medication. However, the relationship between particular genes and the efficacy of MTX treatment for RA patients requires additional investigation.
本研究旨在确定接受甲氨蝶呤（MTX）治疗的类风湿关节炎（RA）患者相关基因的表达，鉴定关键基因，并系统分析这些基因的功能、通路和网络。
从 PubMed 数据库中获取相关文献的 PubMed 标识符（PMID），并使用文本挖掘软件 PubTator 从这些文献中提取基因数据。使用数据库 for Annotation, Visualization and Integrated Discovery（DAVID）获取富集的基因本体论（GO）术语和京都基因与基因组百科全书（KEGG）通路信息。此外，使用 STRING 数据库构建蛋白质-蛋白质相互作用（PPI）网络。与至少 10 个其他基因相互作用的基因被鉴定为关键基因。
共鉴定出 216 个与 MTX 治疗疗效相关的基因，其中 14 条通路表现出显著相关性（p<0.05，FDR<0.05）。此外，构建的 MTX 治疗相关网络由 267 个相互作用组成。发现 14 个基因与至少 10 个其他基因相互作用（p<0.05，FDR<0.05），并在 PPI 网络中被鉴定为关键基因。这些基因是 JAK1、MAPK1、JUN、AKT1、MAPK14、MAPK8、FGB、FN1、ALB、B2M、IL2RB、GGH、IL2RA 和 TP53。
本研究将有助于阐明与 MTX 治疗 RA 疗效相关的分子机制，并为指导患者用药提供科学依据。然而，特定基因与 MTX 治疗 RA 患者疗效之间的关系需要进一步研究。
